Evaluation of In vivo Bioactivity of a Mutated Streptokinase [PDF]
Novelty in Biomedicine, 2017 Background: Immunogenicity of Streptokinase, as a thrombolytic drug, has limited its clinical use. Elimination of the amino acid residues that are responsible for immunogenicity while don’t affect the bioactivity of streptokinase is worthy. Recently, we
Marzieh Sameni +6 more
doaj +3 more sources
Fibrinolytic Activity of Recombinant Mutant Streptokinase [PDF]
Novelty in Biomedicine, 2015 Background: Streptokinase is a bacterial protein produced by different beta hemolytic streptococci and widely used in thrombolytic treatment. The main disadvantage of using streptokinase is antibody formation which causes allergic reaction to neutralize ...
Mahboobeh Mobarrez +3 more
doaj +3 more sources
Transient acute renal failure after coronary thrombolysis with streptokinase [PDF]
Revista Cubana de Medicina Militar, 2021 Introduction: There are currently more than 150 medications related to the appearance of rhabdomyolysis and transient acute renal failure. Streptokinase can be one of them.
Rodolfo Vega Candelario +1 more
doaj +2 more sources
Streptokinase and streptokinase card: questionnaire validation to evaluate knowledge among post‐STEMI patients in a Malaysian Tertiary Hospital [PDF]
, 2020 Background: Although recombinant tissue plasminogen activator has become the first-line thrombolytic agent, streptokinase remains in use in acute ST-elevation myocardial infarction (STEMI) patients in Malaysian public hospitals.
Mohd Puad, Norfarazila +7 more
core +1 more source
Streptokinase-Induced Anaphylaxis [PDF]
, 1989 Streptokinase is a thrombolytic agent used most commonly for the dissolution of thrombi obstructing coronary arteries during acute myocardial infarction (MI). Anaphylactic reactions induced by streptokinase occur rarely.
George E. Matthews +3 more
core +1 more source
Why do patients develop reactions to streptokinase? [PDF]
, 1993 SUMMARY Minor reactions to streptokinase are not uncommon, although the etiology is unknown. It is widely presumed, however, that these, like the more serious immune reactions, are antibody-mediated. We measured specific anti-streptokinase
M LYNCH +3 more
core +1 more source
Liposomes for the delivery of streptokinase [PDF]
, 2017 Streptokinase is an efficient thrombolytic agent used to treat thromboembolic disorders. Conventional streptokinase formulations have limited thrombolytic activity and several shortcomings because of their immunogenicity and dose-related side effects ...
Shivani Verma +2 more
core +1 more source
Antibodies to streptokinase [PDF]
BMJ, 1996 Once is enough Thrombolysis is established treatment in the early management of myocardial infarction, and it reduces 35 day mortality by about a quarter.1 The GUSTO study has suggested some advantage of alteplase (rt-PA) over streptokinase with regard to early patency of the occluded coronary artery.2 In particular, GUSTO has suggested that patients ...
openaire +2 more sources
Activation of rabbit plasminogen by streptokinase [PDF]
, 1965 When streptokinase was injected into whole rabbits the fibrinolytic and proteolytic activity of the plasma increased and antifibrinolytic and antiproteolytic activity and fibrinogen level fell.
Dhurjati P. Chattopadhyay +1 more
core +1 more source
High-dose streptokinase in the treatment of acute massive pulmonary embolism complicated with cardiogenic shock, respiratory arrest and ventricular fibrillation [PDF]
Vojnosanitetski Pregled, 2005 Background. Despite advances in prophylaxis, diagnostic modalities, and therapeutic options, pulmonary embolism remains a commonly undiagnosed entity with lethal outcome. Clinically, pulmonary embolism ranges from massive thromboembolism with cardiogenic
Lasica Ratko +4 more
doaj +1 more source